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Background. The UK Royal College of Pathologists Thy terminology for reporting thyroid FNAC cytology 
was first published in 2009, used throughout the United Kingdom and Ireland, in some parts of Italy and 
Switzerland, and elsewhere. There is no review of the literature or meta-analysis of the risk of malignancy 
(ROM) in the various categories of the UK Thy terminology. The study goal was to establish the published 
ROM for each Thy category and compare results with other existing terminology systems where similar 
meta-analyses were available. 
Methods. A comprehensive literature search of online databases was conducted in May 2019 examining 
the ROM for histologically proven nodules with preoperative FNAC classified according to the UK Thy 
terminology.  
Results. 25 articles were identified showing results of both cytology and histology. 12 of these were 
excluded to prevent selection bias as they showed data in just one Thy category. In the remaining 13 articles 
the pooled ROM was as follows; Thy 1: 12% (± 5-22%;95% CI); Thy 2: 5% (± 3-9%;95% CI); Thy 3: 22% 
(± 18-26%;95% CI); Thy 3a: 25% (± 20-31%;95% CI); Thy 3f: 31% (± 24-39%;95% CI); Thy 4: 79% (± 70-
87%;95% CI); and Thy 5: 98% (± 97-99%; 95% CI) . 
Conclusion. This meta-analysis shows comparable results to meta-analyses of other internationally 
recognised reporting terminologies for pooled risk of malignancy for surgically excised nodules in the 
various Thy reporting categories. There is comparatively little difference (6% only) between the pooled 









The UK Thy terminology for reporting thyroid FNAC cytology was developed in response to the need for a 
standardised reporting terminology for fine-needle aspiration cytology (FNAC), to improve clinical 
management of patients. The first major internationally recognised system for reporting thyroid FNAC was 
the 1996 Papanicolaou Society Guideline [1]. Subsequently, in the UK Newcastle [2] and Portsmouth [3] 
separately published tiered classification systems for in-house reporting of thyroid FNAC, followed in 2002 
by national guidance from The British Thyroid Association (BTA) and The Royal College of Physicians of 
London, Guidelines for the Management of Thyroid Cancer in Adults [4], a second edition in 2007 [5] and 
a third edition in 2014 [6]. After the 2007 Bethesda National Cancer Institute Thyroid Fine Needle 
Aspiration (FNAC) State of the Science Conference [7] in 2009 The UK Royal College of Pathologists 
(RCPath) published the first edition of the Thy terminology [8] and this was revised in 2016 [9]. The current 
2016 RCPath guidance has five major categories, dividing the indeterminate category ‘neoplasm possible-
Thy 3’ into Thy 3a (neoplasm possible – atypia / non-diagnostic) and Thy 3f (neoplasm possible, suggestive 
of  follicular neoplasm) [9]. There is also a separate category for thyroid cysts, Thy 1c. The RCPath guidance 
aligns with The Bethesda System for Reporting Thyroid Cytology (TBSRTC) and other international 
reporting systems for reporting thyroid FNAC cytology, see table 1.  
The purpose of this meta-analysis was to review the peer-reviewed published literature to date to examine 
the stated rate(s) or risk(s) of malignancy (ROM) for patients undergoing thyroid surgery and reported using 
the UK Thy terminology in the various Thy categories.  
 
Material and Methods  
Conduct of review 
This present systematic review was conducted according to Prisma guidelines.  
Search strategy 
A comprehensive literature search was conducted using the online databases; Pubmed/MEDLINE, 
ScopusTM and ISI Web of KnowledgeTM. The search aimed to find original peer reviewed studies describing 





the RCPath ‘Thy’ system with confirmatory histopathological diagnosis. A combination of the search subject 
terms (‘thyroid’ &, ‘cytology’ & ‘Thy’) was applied. A starting date limit of 2008 was applied as the first UK 
national guidance was not published by RCPath until 2009 [8]. The search was updated to May 15, 2019, 
and no language restrictions were used. This approach identified a large number of studies; 
Pubmed/MEDLINE (58), ScopusTM (51) and ISI Web of Science (43)TM. To expand the search, references 
in the retrieved articles were also screened to identify additional studies.  
Study selection 
The study inclusion criterion was peer-reviewed original articles reporting thyroid nodules undergoing FNAC 
before surgery and cytologically classified according to either the first [8] or second editions [9] of The 
RCPath Guidance on the Reporting of Thyroid Cytology Specimens with histological diagnosis information 
included in the reports. Two researchers (DP and MB) independently reviewed the titles and abstracts of 
the retrieved articles, applying the study selection criteria and then all authors independently reviewed the 
full-text of the remaining articles.  Articles or audits available online but not published in peer-reviewed 
journals were excluded including studies describing the histological outcome(s) of two subcategories in the 
same group e.g. Thy 3 & Thy 3a or Thy 3, Thy 3a, and Thy 3f. Studies reporting patients undergoing surgery 
in only one diagnostic grouping, the indeterminate category, ‘neoplasm possible-Thy3’ diagnosis (Thy3, 
Thy3a, Thy3f) were also excluded to avoid potential selection bias as these patients are typically selected 
for surgery based on local institutional and clinical management preferences.  Articles with less than fifty 
patients were also excluded as were articles with overlapping patient or nodule data, and case reports were 
not considered.  
 
Data extraction  
For each included study, the following information was extracted independently in a piloted form: 1) study 
data (authors, year and journal of publication, country of origin); 2) study period; 3) number of cases in any 
Thy category; 4) number of cancers in any RCPath Thy category. Data were cross-checked, and any 
discrepancies were discussed and mutually resolved.  
 





The risk of bias of included studies was assessed independently by two reviewers (DP, PT) through the 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for the following aspects: patient 
selection; index test; reference standard; flow and timing. Risk of bias and concerns about applicability were 
rated as low, high and unclear risk.  
 
Statistical analysis  
A proportion meta-analysis was performed to obtain the pooled rate of histologically proven cancer among 
all nodules within a specific FNAC class. If in a specific analysis there was one study with a single nodule, 
that study was excluded from that specific analysis. For statistical pooling of data, the DerSimonian and 
Laird method (random-effects model) was used [10]. In this model, pooled data represent weighted 
averages related to the sample sizes of studies. Pooled data are presented with 95% confidence intervals 
(95% CI) and displayed using a Forest plot. The I-square index was used to quantify the heterogeneity 
among the studies, and significant heterogeneity was defined as an I-square value > 50%. Egger’s test was 
carried out to evaluate the possible presence of significant publication bias. Significance was set at p<0.05. 




Qualitative analysis (systematic review)  
According to the above search algorithm, 25 articles were selected among the total retrieved online. Out of 
25 articles, 12 were excluded because they reported data in one single RCPath ‘Thy’ terminology category; 
Alexander [11], Mihai [12], Tysome [13], Dutta [14], Lakhani [15], Pagni [16], Wong [17], Rago [18], Brophy 
[19], Trombetta [20], Giusti [21], Khalil [22]. Finally, 13 articles; Agrawal [23], Dallari [24], Deandrea [25], 
Doddi [26], Fadda [27], Gill [28], Glynn [29], Kelly [30], Lobo [31], Mehanna [32], Montgomery [33], Mullen 
[34] and Parkinson [35] were included in the present systematic review and meta-analysis. These 13 studies 
describe a total of 3910 nodules with histological diagnosis and preoperative FNAC assessment according 
to The RCPath Thy terminology.  





Quality assessment of the studies is reported in Table 2. Overall, all studies enrolled consecutive patients 
with thyroid nodules. Of note only one study did not state the study period. Importantly, regarding the 
reference standard (histological diagnosis), there was low risk in all studies.  
 
Quantitative analysis (meta-analysis)  
The 13 articles included in the meta-analysis report the histological outcome of 3910 nodules with 
preoperative FNAC classified according to The RCPath Thy terminology. Of note there were 598 Thy 1, 
1351 Thy 2, 625 Thy 3, 236 Thy 3a, 376 Thy 3f, 319 Thy 4, and 406 Thy 5. Table 3 details data in the 
included 13 articles. As a consequence, it was possible to perform a meta-analysis of all RCPath Thy 
terminology classes except for Thy 1c due to absence of data. Importantly, there are studies reporting data 
for the indeterminate cytological category as a whole (Thy3) and managed by surgery and there are other 
studies reporting data for Thy 3a and Thy 3f separately. In the meta-analysis of Thy 4, the single case in 
the study by Kelly et al. [30] was excluded to avoid bias. Unfortunately, it was not possible to perform a 
meta-analysis of the differing histological subtypes of carcinoma (i.e., papillary, follicular, medullary, 
anaplastic) due to insufficient data. The pooled ROM of the cytological categories was following: 12% in 
Thy 1, 5% in Thy 2, 22% in Thy 3, 25% in Thy 3a, 31% in Thy 3f, 79% in Thy 4, 98% in Thy 5. The most 
statistically powerful results were those for Thy 3a, and Thy 5 which showed absence of heterogeneity. 







The published literature in thyroid FNAC cytology is heterogeneous, and many studies report series of 
cytology cases but without the accompanying histology.  In the 13 articles included in this meta-analysis 
the ROM in the various cytological subcategories were as follows; Thy 1 12% (± 5-22%;95% CI), Thy 2 5% 
(± 3-9%;95% CI), Thy 3 22% (± 18-26%;95% CI), Thy 3a 25% (± 20-31%;95% CI), Thy 3f 31% (± 24-
39%;95% CI) , Thy 4 79% (± 70-87%;95% CI) and Thy 5 98% (± 97-99%; 95% CI). This meta-analysis 
shows comparable results to other internationally recognised reporting terminologies for risk of malignancy 
for surgically excised nodules in the various reporting categories. Without taking account of NIFTP tumours 
the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) shows a ROM for non-
diagnostic/unsatisfactory FNAC of 5-10% which is equivalent to Thy 1, for TBSRTC benign 0-3% equivalent 
to Thy 2, for TBSRTC atypia of undetermined significance/follicular lesion of undetermined significance 
~10-30% equivalent to Thy 3a, for TBSRTC follicular neoplasm/suspicious for a follicular neoplasm 20-
40 %, equivalent to Thy 3f, for TBSRTC suspicious for malignancy 50-75%, equivalent to Thy 4 and for 
TBSRTC malignant 97-99%, equivalent to Thy5 [36]. The reason for the relatively higher rates of 
malignancy in the lower risk groups, Thy 1 (12%) and Thy 2 (5%) is because this meta-analysis is biased 
by the fact that only patients undergoing surgery were included in the analysis. 
 
There is comparatively little difference (6%) in ROM of Thy 3a (25%) and Thy 3f (31%) surgically excised 
nodules. The ROM for Thy 3a FNAC (25%) lies within with the range of ~10-30% seen for TBSRTC atypia 
of undetermined significance/follicular lesion of undetermined significance and the ROM of Thy 3f (31%) 
also lies within the range expected in the Bethesda terminology of 25 to 40% for TBSRTC follicular 
neoplasm/suspicious for a follicular neoplasm [36]. Both the UK and Bethesda terminologies include cases 
with atypia in both indeterminate categories, Thy 3a and Thy 3f, equivalent to TBSRTC atypia of 
undetermined significance/follicular lesion of undetermined significance and TBSRTC follicular 
neoplasm/suspicious for a follicular neoplasm respectively. This explains the similar risk of malignancy seen 
in the two indeterminate categories in both the UK and the Bethesda terminology. The Italian TIR system 
by contrast places cases with atypia in a TIR higher risk indeterminate category, category IIIB, [37] hence 





and higher risk FNAC categories [38]. No meta-analyses of the Japanese or Australian terminologies have 
been undertaken to the authors’ knowledge. 
 
It should be noted that by including only patients undergoing surgery in this meta-analysis there is an 
inevitable bias towards higher rates of malignancy as higher rates of malignancy are seen in patients 
undergoing surgery for thyroid nodules with concerning clinical features; for example clinically or suspicious 
features on ultrasound, patient or clinician preference. This series is therefore risk-biased as it does not 
include patients that have not undergone thyroid surgery who would be expected to have lower ROM’s for 
thyroid nodules that did not undergo surgery.  
 
The published data presented here shows that the UK system is comparable to other terminologies for 
reporting FNAC cytology as it is particularly aligned with the TBSRTC on which it was partially modelled as 
the UK terminology was published shortly after the Bethesda thyroid FNAC cytology state of the science 
conference in 2009. The only major difference between the UK system and the Bethesda system is a 
separate subcategory for cystic lesions, Thy 1c, although this study was unable to identify the effect of Thy 
1c aspirates due to low numbers of cases and lack of surgical pathology correlation. Of the terminology 
systems in use in Europe the Italian system gives greater separation of the subcategories in indeterminate 
categories TIR 3A & TIR 3B [36].  
The introduction of NIFTP terminology in 2016 and its incorporation into the World Health Organization 
Classification of Tumours of Endocrine Organs in 2017 [39] would be expected to reduce the risk of 
overdiagnosis of encapsulated follicular variant of papillary thyroid carcinoma [40]. In some areas of the 
world pre-2016 the rate of diagnosis of encapsulated follicular variant of papillary thyroid carcinoma was 
extremely high [39] although in the UK this was a comparatively rare [41] diagnosis. TBSRTC in 2017 
adopted NIFTP terminology and provided two ranges of risk of malignancy, one which considers NIFTP as 
a malignant tumour the other which does not [36]. All the studies included in this meta-analysis predate 
introduction of NIFTP terminology and hence the issue of NI FTP was not discussed in any of the published 
articles included in this analysis. The limitations of the study are that it does not include nonoperated 





aspect that this analysis makes clear is that there is no over-arching national registry for thyroid nodules in 
the UK or elsewhere to the authors’ knowledge, and systems for data collectionfor thyroid nodule and 
thyroid cancer patients require further development. This study confirms the validity and clinical applicability 
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Table 1 Internationally used terminology systems for Thyroid FNAC Cytology 









































Normal or benign 
Thy3a 
Neoplasm 












































































Table 2. Quality assessment of the studies according to QUADAS-2. 
 Risk of bias Feasibility 














Agrawal L L L L L L L 
Dallari U U L L L L L 
Deandrea U L L L L L L 
Doddi L L L L L L L 
Fadda U L L L U L L 
Gill H L L H H L L 
Glynn L L L L L L L 
Kelly L U L L L L L 
Lobo L L L L L L L 
Mehanna L L L L L L L 
Montgomery H L L L H L L 
Mullen L L L L L L L 
Parkinson L L L L L L L 
 







Table 3. Data retrieved in the studies included in the systematic review. 
First author (ref) Thy1 Thy2 Thy3 Thy3a Thy3f Thy4 Thy5 
Agrawal - 174 7 - - 4 18 
Dallari - 29 33 - - 7 18 
Deandrea 51 319 294 - - 91 172 
Doddi 269 287 48 - - 11 6 
Fadda - 8 50 - - 59 3 
Gill 93 78 - 67 88 - - 
Glynn 16 30 55 - - 8 9 
Kelly - 79 21 - - 1 5 
Lobo - - - 10 72 11 43 
Mehanna 28 88 117 - - - - 
Montgomery - - - - - 40 25 
Mullen - 80 - 7 52 21 36 










Table 4. Results of the meta-analyses. 
 Cancer prevalence (95% CI) Consistency – I2 (95% CI) Egger test (p) 
Thy1 12 (5 to 22) 88.7% (77.2 to 93.1) 0.025 
Thy2 5 (3 to 9) 80.7% (64.2 to 87.7) 0.005 
Thy3 22 (18 to 26) 27.8% (0 to 67.5) 0.011 
Thy3a 25 (20 to 31) 0% (0 to 67.9) 0.896 
Thy3f 31 (24 to 39) 59% (0 to 84.3) 0.790 
Thy4 79 (70 to 87) 65.5% (16 to 80.8) 0.365 
Thy5 98 (97 to 99) 0% (0 to 51.2) 0.321 
 
 
